Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases.

S-1360, a 1,3-diketone derivative, was the first HIV integrase inhibitor to enter human trials. Clinical data suggested involvement of non-cytochrome P450 clearance pathways, including reduction and glucuronidation. Reduction of S-1360 generates a key metabolite in humans, designated HP1, and constitutes a major clearance pathway. For characterization of subcellular location and cofactor dependence of HP1 formation, [(14)C]-S-1360 was incubated with commercially available pooled human liver fractions, including microsomes, cytosol, and mitochondria, followed by HPLC analysis with radiochemical detection. Incubations were performed in the presence and absence of the cofactors NADH or NADPH. Results showed that the enzyme system responsible for generation of HP1 in vitro is cytosolic and NADPH-dependent, implicating aldo-keto reductases (AKRs) and/or short-chain dehydrogenases/reductases (SDRs). A validated LC/MS/MS method was developed for investigating the reduction of S-1360 in detail. The reduction reaction exhibited sigmoidal kinetics with a K(m,app) of 2 microM and a Hill coefficient of 2. The ratio of V(max)/K(m) was approximately 1 ml/(min mg cytosolic protein). The S-1360 kinetic data were consistent with positive cooperativity and a single enzyme system. The relative contributions of AKRs and SDRs were examined through the use of chemical inhibitors. For these experiments, non-radiolabeled S-1360 was incubated with pooled human liver cytosol and NADPH in the presence of inhibitors, followed by quantitation of HP1 by LC/MS/MS. Quercetin and menadione produced approximately 30% inhibition at a concentration of 100 microM. Enzymes sensitive to these inhibitors include the carbonyl reductases (CRs), a subset of the SDR enzyme family predominantly located in the cytosol. Flufenamic acid and phenolphthalein were the most potent inhibitors, with > 67% inhibition at a concentration of 20 microM, implicating the AKR enzyme family. The cofactor dependence, subcellular location, and chemical inhibitor results implicated the aldo-keto reductase family of enzymes as the most likely pathway for generation of the major metabolite HP1 from S-1360.

[1]  L. Amzel,et al.  Structures of mammalian cytosolic quinone reductases. , 2000, Free Radical Biology & Medicine.

[2]  A. Atalla,et al.  Carbonyl reduction of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by cytosolic enzymes in human liver and lung. , 2000, Cancer letters.

[3]  Nouri Neamati,et al.  Patented small molecule inhibitors of HIV-1 integrase: a 10-year saga , 2002 .

[4]  A. Skalka,et al.  The retroviral enzymes. , 1994, Annual review of biochemistry.

[5]  A. Somogyi,et al.  Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol. , 2000, British journal of clinical pharmacology.

[6]  J B Houston,et al.  In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[7]  T. Penning,et al.  The aldo-keto reductase superfamily homepage. , 2003, Chemico-biological interactions.

[8]  A. Hara,et al.  Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. , 2002, Biological & pharmaceutical bulletin.

[9]  Amy S. Espeseth,et al.  Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Houston,et al.  Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat. , 1999, The Journal of pharmacology and experimental therapeutics.

[11]  R. Gulick New antiretroviral drugs. , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  M. Martin,et al.  Molecular organization of the AIDS retrovirus , 1985, Cell.

[13]  D. Hazuda,et al.  Inhibition of HIV-1 Ribonuclease H by a Novel Diketo Acid, 4-[5-(Benzoylamino)thien-2-yl]-2,4-dioxobutanoic Acid* , 2003, The Journal of Biological Chemistry.

[14]  M. Lewis,et al.  Comparative anatomy of the aldo-keto reductase superfamily. , 1997, The Biochemical journal.

[15]  Erik De Clercq New developments in anti-HIV chemotherapy. , 2001 .

[16]  A. Fauci,et al.  The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. , 1988, Science.

[17]  Y. Kallberg,et al.  Coenzyme-based functional assignments of short-chain dehydrogenases/reductases (SDRs). , 2003, Chemico-biological interactions.

[18]  L. Amzel,et al.  Structure and mechanism of cytosolic quinone reductases. , 1999, Biochemical Society transactions.

[19]  T. Tracy,et al.  Atypical kinetic profiles in drug metabolism reactions. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[20]  Marc C Nicklaus,et al.  Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S). , 2003, Molecular pharmacology.

[21]  T. Nakayama,et al.  Structural and functional comparison of two human liver dihydrodiol dehydrogenases associated with 3 alpha-hydroxysteroid dehydrogenase activity. , 1992, The Biochemical journal.

[22]  Haiching Ma,et al.  Structure-function aspects and inhibitor design of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) , 2001, Molecular and Cellular Endocrinology.

[23]  K. Neet,et al.  Transients and cooperativity. A slow transition model for relating transients and cooperative kinetics of enzymes. , 1972, The Journal of biological chemistry.

[24]  D. Ross,et al.  NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. , 2000, Chemico-biological interactions.

[25]  H. Jörnvall,et al.  Forms and functions of human SDR enzymes. , 2001, Chemico-biological interactions.

[26]  H. Thijssen,et al.  Stereoselective acetonyl side chain reduction of warfarin and analogs. Partial characterization of two cytosolic carbonyl reductases. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[27]  Yun Tang,et al.  Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. , 2002, Journal of medicinal chemistry.

[28]  E. Maser,et al.  Purification, characterization and NNK carbonyl reductase activities of 11beta-hydroxysteroid dehydrogenase type 1 from human liver: enzyme cooperativity and significance in the detoxification of a tobacco-derived carcinogen. , 2003, Chemico-biological interactions.

[29]  A. Hara,et al.  Kinetic studies of the inhibition of a human liver 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase isozyme by bile acids and anti-inflammatory drugs. , 1995, Biological and Pharmaceutical Bulletin.

[30]  K. Nill,et al.  High-affinity stereoselective reduction of the enantiomers of ketotifen and of ketonic nortriptyline metabolites by aldo-keto reductases from human liver. , 2000, Biochemical pharmacology.

[31]  S. Ekins,et al.  Autoactivation and activation of the cytochrome P450s. , 1998, International journal of clinical pharmacology and therapeutics.

[32]  H. Shiraishi,et al.  Roles of the C-terminal domains of human dihydrodiol dehydrogenase isoforms in the binding of substrates and modulators: probing with chimaeric enzymes. , 1998, The Biochemical journal.

[33]  A. D. Rodrigues,et al.  Enzyme kinetics of cytochrome P450-mediated reactions. , 2012, Current drug metabolism.

[34]  J. Walsh,et al.  The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes. , 2002, Chemico-biological interactions.

[35]  U. Oppermann,et al.  Molecular and structural aspects of xenobiotic carbonyl metabolizing enzymes. Role of reductases and dehydrogenases in xenobiotic phase I reactions. , 2000, Toxicology.

[36]  A. Atalla,et al.  Purification and characterization of oxidoreductases-catalyzing carbonyl reduction of the tobacco-specific nitrosamine 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human liver cytosol , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[37]  D. Cohen,et al.  The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[38]  N. Bachur,et al.  Adriamycin metabolism in man. Evidence from urinary metabolites. , 1976, Drug metabolism and disposition: the biological fate of chemicals.

[39]  Hara,et al.  Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. , 1995, Biochemical pharmacology.

[40]  A. Rettie,et al.  Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. , 1998, Biochemistry.